Search result for 'ryaltris'

Glenmark Pharmaceuticals reported a consolidated profit after tax of Rs 354.49 crore in the second quarter ended on September 30, 2024, a significant turnaround from the previous year's loss. The...

Glenmark Pharmaceuticals is recalling two products in the US, Ryaltris Nasal Spray and Ciclopirox Gel, due to manufacturing defects. The USFDA has classified the recalls as Class II and Class III.

Glenmark Pharmaceuticals reported a two-fold increase in net profit to Rs 340 crore for Q1 FY24, driven by strong revenue growth and improved margins.

Glenmark Pharmaceuticals expects its nasal spray Ryaltris to reach USD 80 million in sales next year, boosting revenue. The drug, commercialized in 31 markets, treats allergic rhinitis.